

AGENDA – SRI LANKA HIGH LEVEL VISIT TO THE UK

National Institute for Health and Care Excellence 10 Spring Gardens | London SW1A 2BU | United Kingdom

NICE International
www.nice.org.uk/niceinternational



Objective:

The visit will provide an opportunity for 10-12 high level individuals from the Sri Lankan government to gain an understanding of the work of the UK's National Institute for Health and Care Excellence (NICE) and its functioning within the wider National Health Service (NHS). There will be a particular focus on performance based payment / results based financing and how these are operationalized in the NHS, in particular in the context of primary care, secondary care and commissioning

Indicative speakers (subject to availability and confirmation)

Dr Amanda Adler, Chair, NICE Technology Appraisal Committee (AA)

Sandor Beukers, Team Leader, MHRA (SBr)

Stephen Brookfield, Associate Director, Costing and Commissioning (SB)

Dr Kalipso Chalkidou, Director, NICE International (KC)

Dr Françoise Cluzeau, Associate Director, NICE International (FC)

Nigel Edwards, Research Fellow, King's Fund (NE)

Chris Gibbons, Data Analyst Health Technology Intelligence, Impact and Evaluation NICE (CG)

Pam Griffiths, Programme Manager, Evaluation and Uptake, NICE (PG)

Dr Sandy Gupta, MD FRCP, Consultant Cardiologist, Whipps Cross/BartsHealth NHS Trusts, London (SG)

Professor David Haslam, Chairman, NICE (DH)

Dr Margaret Helliwell, Vice Chair (NICE) (MH)

Dr Latha Hapugoda, Associate Director Public Health/ Consultant in Public Health Medicine, NHS North East London & the City (LH)

Terence Lacey Quality Standards and Indicators, NICE (TL)

Heidi Livingstone, Public Involvement Adviser, NICE Patient and Public Involvement (HL)

Prof Neal Maskrey, Programme Director, Medicines Prescribing Centre (NM)

Dr Antony Morgan, Associate Director, Centre for Public Health, NICE (AM)

Sarah Morgan, Group Manager, MHRA (SM)

Dominick Moran, Data Analyst, Commissioning, Impact and Evaluation NICE (DM)

Jan Robinson, Programme Manager, Research and Development, NICE (JR)

Satish Singh, Expert Clinical Assessor, Licensing Division, MHRA (SS)

Thomas Wilkinson, Adviser (Health Economics), NICE International (TW)

Andrew Wragg, Quality Standards and Indicators, NICE (AW)

Mark Birse, Group Manager, Inspections MHRA (MB)

Stephen Young, Head of Analytical Science, MHRA (SY)



Day 1 – Monday 22nd April

Conwy

Overview of the NHS and NICE; NICE guidance (1) – clinical guideline and pathways, quality standards, disease prevention guidelines

Time	Item	Who	Overview
9.00	Welcome to NICE & overview of visit	DH	
9.20	Introduction to the British National Health Service (NHS) – principles, structures and financing mechanisms	NE	<ul style="list-style-type: none"> • Financing and payment mechanisms • Provider/purchaser split • The roles of providers, purchasers and government
10.20	Introduction to NICE and its role in the NHS	KC	<ul style="list-style-type: none"> • Political and practical steps leading to the establishment of NICE, and its evolution since • Governance, budgets and business planning • Links with government and academic groups
11.30	break		
11.45	Development of NICE guidelines and clinical pathways	FC	<ul style="list-style-type: none"> • How guidelines & pathways are developed • Who is involved • How is the evidence searched assessed and how decisions are made
13.00	lunch		
14.00	Development of quality standards	AW & TL	
15.30	Break		
16.00	Development of guidance on health promotion and disease prevention at the population level	AM	
17.00	NICE in action - the setting of Cardiology in the real world	SG	
17.30	End		



Day 2 – Tuesday 23rd April


Field trips / Observe meetings

	<p>Option 1: Observe NICE Technology Appraisal committee meeting America Conference Centre, 17 Crosswall, London EC3N 2LB</p>
9.30	<p>Meet at NICE offices to travel to America Conference Centre</p>
	<p style="text-align: center;">NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Health Technology Evaluation Technology Appraisal (Committee B) Meeting</p> <p style="text-align: center;"><i>The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00.</i> Please note that this agenda is subject to change prior to the meeting</p> <ol style="list-style-type: none"> 1. Welcome and introduction to format of meeting 2. Apologies 3. Any other business Confidential 4. Minutes from the last Committee meeting held on 20 February 2013 and 22 January 2013 5. Appraisal of Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review of TA95 and TA120) <ol style="list-style-type: none"> 5.1. Declarations of interest Part 1 only (open session) 5.2. Introduction by the Chair Dr Amanda Adler Part 1 only (open session) 5.3. Presentation by lead team, Mr Terry Lewis, Professor Stephen Palmer and Professor Ken Stein Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). Part 1 AND part 2 (open and closed session) 5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) Part 2 only (closed session) 6. Appraisal of eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (review of technology appraisal 205) <ol style="list-style-type: none"> 6.1. Declarations of interest. Part 1 only (open session)



Day 2 – Tuesday 23rd April

Field trips / Observe meetings

	<p>Option 2: Visit to the Medicines and Healthcare products Regulatory Agency 151 Buckingham Palace Road, London SW1W 9SZ Meeting Room R.M. 507 (5th floor)</p>	
9.00	Meet at NICE offices to travel to MHRA	
9.30	Presentation about MHRA, EU and International Policy and Strategy, Policy Division.	SBr
10.00	Post-marketing surveillance - Vigilance and Risk Management of Medicines	SM
11.00	Licensing of medicines and medical devices in the UK/EU	SS
11.45	Good Manufacturing Practices	MB
12.45	Short break-lunch	
13.00	Analytical Science	SY
13.45	Wrap-up	
14.15	Travel back to the NICE Offices & end of day 2	



Day 2 – Tuesday 23rd April

Field trips / Observe meetings

	Option 3&4: Medical Education Centre Whipps Cross University Hospital Leytonstone London E11 1NR	
11.00	<i>Meet at NICE offices to travel to Whipps Cross University Hospital</i>	
12.00	Implementing NICE Guidance in Cardiology	SG
13.30	<i>Lunch break</i>	
14.00	Continuation on Implementing NICE Guidance in Cardiology	SG
14.30	Commissioning cycle & operational aspects	LH
15.00	<i>Tea break</i>	
15.15	NICE Guidance/Quality standards with special reference to Diabetes	LH
16.00	<i>Travel back to NICE offices and end of day</i>	



Day 3 – Wednesday 24th April
Conwy

Time	Item	Who	Overview
09.00	Health Technology Assessment in the UK and the role of NICE	TW	<ul style="list-style-type: none"> • NICE Technology Appraisals – principles and processes • The role of Health Technology Assessment in NICE guidelines and Quality Standards • Medtech and diagnostics assessment programmes
10.15	The Citizens’ Council and the role of social value judgements in decision making	JR	
11.30	Break		
11.45	The Medicines Prescribing Centre: supporting rational prescribing through academic detailing, local formularies and briefings for off-label use	NM	
13.00	Lunch		
14.00	Clinical audit and clinical governance and the role of evidence-informed clinical standards	MH	
16.00	End of day 3		



Day 4 – Thursday 25th April

Thames

Time	Item	Who	Overview
09.00	Engaging patients and the public in NICE guidance	HL	<ul style="list-style-type: none"> • How NICE engages the public in its guidance • Recruiting, training and supporting patients
10.00	Drug pricing in the UK	TW	<ul style="list-style-type: none"> • The Pharmaceutical Pricing and Reimbursement Scheme (2009 version) • Pricing and Reimbursement Review by the Office of Fair Trading 2007: the beginnings of Value Based Pricing • Demand-side mechanisms: limited co-payments; policies to encourage the use of generics
10.45	Patient Access Schemes and price negotiations in the context of the NHS	TW	
11.15	Break		
11.30	Implementation through pay for performance schemes	SB	<p>Implementation of NICE guidance:</p> <ul style="list-style-type: none"> • Costing support • Assessment of budget impact • Provider contracts, HRGs and the Tariff <p>Results based financing incentives and systems in the National Health Service</p> <ul style="list-style-type: none"> • QOF (Primary care) • COF (Secondary care) • CQUIN (Commissioning) • Institutional basis of RBF programmes
12.30	Analysis of drug usage and uptake of guidance	DM, CG & PG	
13.30	Lunch & Discussion on possible next steps, areas for collaboration and future visits	KC & RP	
15.00	End of day 4		